10 employees
Artielle ImmunoTherapeutics develops recombinant T-cell receptor ligands to treat T-cell-mediated inflammatory diseases.
2004
$11M
from 2 investors over 2 rounds
Artielle ImmunoTherapeutics raised $11M on June 23, 2004
Investors: Pelion Venture Partners and Sanderling Ventures